Cargando…

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation

The age of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) has increased during the last decades, mainly due to improved reduced-intensity/toxicity conditioning protocols. A reduced-intensity conditioning based on fludarabin, carmustin/BCNU and melphalan (FBM) has been p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duque-Afonso, Jesús, Ihorst, Gabriele, Waterhouse, Miguel, Zeiser, Robert, Wäsch, Ralph, Bertz, Hartmut, Yücel, Mehtap, Köhler, Thomas, Müller-Quernheim, Joachim, Marks, Reinhard, Finke, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319212/ https://www.ncbi.nlm.nih.gov/pubmed/32591641 http://dx.doi.org/10.1038/s41409-020-0986-2

Ejemplares similares

The impact of pulmonary function in patients undergoing autologous stem cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2021)

Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis
por: Rettig, Andrés R., et al.
Publicado: (2021)

A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
por: Schäfer, Henning, et al.
Publicado: (2021)

Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2020)

Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2021)

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
por: Greil, Christine, et al.
Publicado: (2019)

Cellular and Humoral SARS-CoV-2 Vaccination Responses in 192 Adult Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Meyer, Thomas, et al.
Publicado: (2022)

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial
por: Finke, Jürgen, et al.
Publicado: (2022)

Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation
por: Waterhouse, Miguel, et al.
Publicado: (2022)

Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
por: Biavasco, Francesca, et al.
Publicado: (2022)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
por: Kalwak, Krzysztof, et al.
Publicado: (2020)

Reduced Intensity Allogeneic Hematopoietic Cell Transplantation using Fludarabine-Melphalan conditioning for Treatment of Mature T-cell Lymphomas
por: Delioukina, Maria, et al.
Publicado: (2011)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
por: Frankiewicz, Andrzej, et al.
Publicado: (2018)

Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
por: Kutzke, Jade L., et al.
Publicado: (2022)

MBCL-22. EFFICACY OF DOUBLE-CONDITIONING REGIMEN COMPRISING THIOTEPA AND MELPHALAN FOR RELAPSED MEDULLOBLASTOMA – A SINGLE INSTITUTION EXPERIENCE
por: Yamasaki, Kai, et al.
Publicado: (2020)

Cardiopulmonary performance in allogeneic hematopoietic cell transplantation recipients—evaluation of pre-transplant risk assessments
por: Pahl, Antonia, et al.
Publicado: (2021)

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
por: Wu, Ran, et al.
Publicado: (2023)

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation
por: Patel, Khilna, et al.
Publicado: (2016)

Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
por: Bonifazi, Francesca, et al.
Publicado: (2022)

Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
por: Strüßmann, Tim, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors
por: Hara, Junichi, et al.
Publicado: (2022)

Comparison of graft versus host disease with three different alemtuzumab schedules in unrelated donor fludarabine and melphalan allografts
por: Green, Kile, et al.
Publicado: (2017)

Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma
por: Avenoso, Daniele, et al.
Publicado: (2023)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2019)

Whither thiotepa (for patients in the USA)?
por: Dardis, Christopher, et al.
Publicado: (2015)

Correction: High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors
por: Hara, Junichi, et al.
Publicado: (2022)

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
por: Tran, Misha C., et al.
Publicado: (2022)

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
por: Holtan, S G, et al.
Publicado: (2010)

Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
por: Engelhardt, Monika, et al.
Publicado: (2020)

Thiotepa in the treatment of advanced breast cancer.
por: Lyons, A. R., et al.
Publicado: (1965)

Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine
por: Giannotti, Federica, et al.
Publicado: (2018)

Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
por: Waterhouse, Miguel, et al.
Publicado: (2020)

Correction: Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
por: Waterhouse, Miguel, et al.
Publicado: (2021)

Rehabilitation after Allogeneic Haematopoietic Stem Cell Transplantation: A Special Challenge
por: Bertz, Hartmut
Publicado: (2021)

Carmustine-Induced Phosphatidylserine Translocation in the Erythrocyte Membrane
por: Jilani, Kashif, et al.
Publicado: (2013)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nsmq35f57np4fu7qq6f19bveer